# Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/purpose-and-content-of-use-related-risk-analyses-for-drugs-biological-products-and-combination-products/53619b8d-27a9-4506-b006-144d1a9be3d4

> FDA guidance document: Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products. Issue date: July 08, 2024. Get complete insights and analysis.

---

## Details

- Title: Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products
- Communication Type: Guidance Document
- Product Type: devices
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-07-08
- Comment Close Date: 2024-09-09
- Last Changed: 2024-07-09
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2024-D-2484">FDA-2024-D-2484</a>

## Related Documents

- [Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-for-prevention-or-treatment/30eba576-b6ea-4536-918e-e634aefadcc4)
- [Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/setting-endotoxin-limits-during-development-of-investigational-oncology-drugs-and-biological-products-guidance-for-industry-draft-guidance-for-industry/ef751a3a-e9d6-4489-b86d-73f2411682c1)
- [Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/indications-and-usage-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/7d286113-df13-47f4-bc30-1a4d819e56c9)